Neurorestoration of Sustained Attention in a Model of HIV-1 Associated Neurocognitive Disorders

被引:12
|
作者
Moran, Landhing M. [1 ]
McLaurin, Kristen A. [1 ]
Booze, Rosemarie M. [1 ]
Mactutus, Charles F. [1 ]
机构
[1] Univ South Carolina, Dept Psychol, Program Behav Neurosci, Columbia, SC 29208 USA
来源
关键词
S-Equol; gut-brain axis; phytoestrogen; dose response; HIV-1 transgenic rat; ESTROGEN-RECEPTOR-BETA; GASTROINTESTINAL MUCOSA; ANTIRETROVIRAL THERAPY; PREFRONTAL CORTEX; IMMUNE ACTIVATION; SOY ISOFLAVONES; LIFE EXPECTANCY; SEX-DIFFERENCES; TRANSGENIC RAT; MOUSE MODEL;
D O I
10.3389/fnbeh.2019.00169
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Due to the sustained prevalence of human immunodeficiency virus (HIV)-1 associated neurocognitive disorders (HAND) in the post-combination antiretroviral therapy (cART) era, as well as the increased prevalence of older HIV-1 seropositive individuals, there is a critical need to develop adjunctive therapeutics targeted at preserving and/or restoring neurocognitive function. To address this knowledge gap, the present study examined the utility of S-Equol (SE), a phytoestrogen produced by gut microbiota, as an innovative therapeutic strategy. A signal detection operant task with varying signal durations (1,000, 500, 100 ms) was utilized to assess sustained attention in HIV-1 transgenic (Tg) and control animals. During the signal detection pretest assessment, HIV-1 Tg animals displayed profound deficits in stimulus-response learning and sustained attention relative to control animals. Subsequently, between 6 and 8 months of age, HIV-1 Tg and control animals were treated with a daily oral dose of either placebo or SE (0.05, 0.1, 0.2 mg) and a posttest assessment was conducted in the signal detection operant task with varying signal durations. In HIV-1 Tg animals, a linear decrease in the number of misses at 100 ms was observed as SE dose increased, suggesting a dose response with the most effective dose at 0.2 mg SE, approximating controls. Comparison of the number of misses across signal durations at the pretest and posttest revealed a preservation of neurocognitive function in HIV-1 Tg animals treated with 0.2 mg SE; an effect that was in sharp contrast to the neurocognitive decline observed in HIV-1 Tg animals treated with placebo. The results support the utility of 0.2 mg SE as a potential efficacious neuroprotective and/or neurorestorative therapeutic for sustained attention, in the absence of any adverse peripheral effects, in the HIV-1 Tg rat. Thus, the present study highlights the critical need for further in vivo studies to elucidate the full potential and generalizability of phytoestrogen treatment for HAND.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Microglial HIV-1 Expression: Role in HIV-1 Associated Neurocognitive Disorders
    Li, Hailong
    McLaurin, Kristen A.
    Illenberger, Jessica M.
    Mactutus, Charles F.
    Booze, Rosemarie M.
    [J]. VIRUSES-BASEL, 2021, 13 (05):
  • [2] Molecular Signatures of HIV-1 Envelope Associated with HIV-Associated Neurocognitive Disorders
    Teresa H. Evering
    [J]. Current HIV/AIDS Reports, 2018, 15 : 72 - 83
  • [3] Molecular Signatures of HIV-1 Envelope Associated with HIV-Associated Neurocognitive Disorders
    Evering, Teresa H.
    [J]. CURRENT HIV/AIDS REPORTS, 2018, 15 (01) : 72 - 83
  • [4] Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders
    Amila Omeragic
    Olanre Kayode
    Md Tozammel Hoque
    Reina Bendayan
    [J]. Fluids and Barriers of the CNS, 17
  • [5] Potential pharmacological approaches for the treatment of HIV-1 associated neurocognitive disorders
    Omeragic, Amila
    Kayode, Olanre
    Hoque, Md Tozammel
    Bendayan, Reina
    [J]. FLUIDS AND BARRIERS OF THE CNS, 2020, 17 (01)
  • [7] HIV-1 neurocognitive disorders and chemokine receptors
    Barroga, CF
    Ellis, R
    Nelson, J
    Heaton, RK
    Atkinson, JH
    McCutchan, JA
    Grant, I
    Spector, SA
    [J]. AIDS, 1997, 11 (13) : 1651 - 1652
  • [8] Prepulse Inhibition: A Diagnostic Biomarker for HIV-1 Associated Neurocognitive Disorders (HAND)
    McLaurin, Kristen A.
    Mactutus, Charles F.
    Booze, Rosemarie M.
    Fairchild, Amanda J.
    [J]. JOURNAL OF NEUROVIROLOGY, 2019, 25 (SUPPL 1) : S29 - S29
  • [9] UTILITY OF LIF TO PROTECT AGAINST HIV-1 ASSOCIATED NEUROCOGNITIVE DISORDERS.
    Alves, J. M.
    Hunter, R. M.
    Cruz, M. L.
    Ramos, K.
    Velazquez, B.
    Noel, R.
    [J]. JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2016, 11 : S4 - S4
  • [10] An initial screening for HIV-associated neurocognitive disorders of HIV-1 infected patients in China
    Yulin Zhang
    Luxin Qiao
    Wei Ding
    Feili Wei
    Qingxia Zhao
    Xicheng Wang
    Ying Shi
    Ning Li
    Davey Smith
    Dexi Chen
    [J]. Journal of NeuroVirology, 2012, 18 : 120 - 126